



Online

28nd December, 2020

Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G. Block, Bandra- Kurla Complex, Bandra East, Mumbai-400 051 **Corporate Relationship Department BSE Ltd.** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001

Symbol- DHANUKA

Scrip Code : 507717

Sub: Outcome of Investor Group Meet held on December 23, 2020 hosted by Antique Stock Broking Limited.

Dear Sir,

In furtherance to our letter dated December 22, 2020 with respect to "Investor Group Meeting" held on December 23, 2020 hosted by Antique Stock Broking Limited through virtual mode, please find enclosed the outcome of the aforesaid meet in pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015,

Please take above information in your record.

Thanking You,

Yours faithfully,

For Dhanuka Agritech Limited

Jitin Sadana Company Secretary Compliance Officer FCS-7612

Enc/-

Current Reco	:	BUY
Previous Reco	:	BUY
СМР	:	INR737
Target Price	:	INR990
Potential Return	:	34%

Manish Mahawar +91 22 4031 3433 manish.mahawar@antiquelimited.com

Himanshu Binani +91 22 4031 3417 himanshu.binani@antiquelimited.com

Amit Zade +91 22 4031 3395 amit.zade@antiguelimited.com

Market data

Sensex	:	46,974
Sector	:	Agrochemicals
Market Cap (INRbn)	:	35.1
Market Cap (USDbn)	:	0.477
O/S Shares (m)	:	47.6
52-wk HI/LO (INR)	:	936/261
Avg Daily Vol ('000)	:	64
Bloomberg	:	DAGRIIN
Source: Bloomberg		
Valuation		

	FY21e	FY22e	FY23e
EPS (INR)	41.1	48.1	55.1
BVPS (INR)	181.3	219.8	265.2
P/E (x)	18.0	15.3	13.4
P∕BV (x)	4.1	3.4	2.8
RoE (%)	24.9	24.0	22.7

Source: Company, Antique


Returns (%)									
	1m	3m	6m	12m					
Absolute	5	(4)	5	90					
Relative	(1)	(25)	(22)	68					
0 01									

Source: Bloomberg

Shareholding pattern

Promoters	:	75%	
Public	:	25%	
Others	:	0%	

Source: Bloomberg



MANAGEMENT MEET UPDATE

Dhanuka Agritech

Confident to achieve growth guidance; Maintain Buy

We interacted with Mr. M. K. Dhanuka, Managing Director of Dhanuka Agritech (Dhanuka) to understand the current business environment. Key highlights are 1) confident to achieve 2HFY21/FY21 revenue growth guidance of 10%+/22% YoY 2) healthy performance of few top selling products like Targa Super, Chempa, M1, & Luster; (3) RM prices specially generic have started inching up (4) product launches well on track, launched 4 new products in 1HFY21; (5) Innovation turnover index to be in the range of 13-15% by FY22 versus 12% in FY20; (6) formulation unit in Dahej to come in 12-18months. Dhanuka has strong distribution led business model with robust RoE (>21%) as well as balance sheet. We expect that Dhanuka to clock revenue/PAT CAGR of 14%/23% over FY20-FY23E led by improved demand scenario and ramp-up in margins. We maintain 'BUY' with TP of INR990 based on 18xFY23E EPS (10-year high/low 34x/5x, average 19x).

Confident to achieve FY21 revenue growth guidance albeit on slow 3Q

Dhanuka has shown stellar performance in 1HFY21 with revenue/EBITDA/PAT growth of 35%/65%/63% YoY. However, industry growth was muted in Oct/Nov led by a) prolonged rainfall especially in the southern India (contributes 1/3rd of the industry's agrochemicals sales) and b) two cyclones in Nov'20 has resulted into lower consumption of agrochemicals. Further, insecticide category got impacted severely due to lower pest infestations. However, herbicide and fungicide categories are continues to do well. The company has witnessed healthy performance in few top selling products like Targa Super, Chempa, M1, & Luster. **Dhanuka expects to grow 10%+ YoY in 2HFY21 and confident to achieve revenue growth guidance of 22% YoY in FY21.**

Raw materials have started inching up; likely to take final product price hike during 4QFY21

Raw material prices especially generic started inching up led by (1) depreciating Chinese Yuan against USD; and (2) sharp jump in freight cost from China (almost 3x recently) on account of lower container availability at ports. The company is passing on the higher raw material prices to farmers. However, it will reflect from 4QFY21 onwards. **Overall, management remains confident to expand EBITDA margin by 100bps+ YoY in FY21 on a conservative basis.**

Dahej formulation capex to come on stream in 12-18months, API capex is yet to finalise

Dhanuka is setting up its 4th formulation unit in GIDC, Dahej with capex of INR0.5-0.6bn and it is expected to come on stream over 12-18months. It could have asset turnover of 5-6x at optimal utilisation. Moreover, Dhanuka is planning to set up API manufacturing unit in Dahej. However, it is at early stage of consideration and is expected to be finalised in the next 3-4months.

Product launches to continue

During 1HFY21, Dhanuka has launched 4 products as against a guidance of 4-5 products in FY21. Out of this, 2 products are in 9(3) category (Kirari and Nissodium) and rest two products are in 9(4) category (Dabooch and Dozo Maxx). The company envisaged to launch 4-5 products per annum going forward. Further, Innovation turnover index (ITI) for FY21 is likely to be lower YoY basis considering high base of last year (Cover and Luster were included in last year's ITI). **Dhanuka remains confident to improve ITI to 13-15% by FY22E (v/s 12%/11% in FY20/2QFY21) led by robust pipeline of new launches.**

	Sakura - 9(3)	Weedicide		
	Mortar	Insecticide		
FY15	Pager	Insecticide		
	Jackal	Insecticide		
	Dhanvarsha	Plant Growth Enchancer		
	Dozo	Herbicide		
FY16	Goldy - 9(4)	Fungicide		
	Cover	Insecticide		
	Thiram			
	Maxx-Soy	Herbicides		
	Conika	Fungicide		
FY17	Fujita	Fungicide		
	Hi-Dice Super	Fungicide		
	Bullon	Insecticide		
	Aashito	Insecticide		
	Delight	Fungicide		
	Dumil	Herbicides		
	Fenox - 1000	Herbicides		
	Godiwa	Fungicide		
	Godiwa Super	Fungicide		
FY18	Marker Super	Insecticide		
	D-one	Insecticide		
	Suelo	Soil Health Enhancer		
	Domar	Insecticide		
	Apply	Insecticide		
FY19	Largo	Thripicide		
	Chempa	Herbicide		
	Mycore	Soil Health Enhancer		
FY20	Zapac	Insecticide		
1127	Pro-rin	Insecticide		
	Prodhan	Insecticide		
	Dabooch	Herbicide		
1HFY21	Dozo Maxx	Herbicide		
177121	Kirari	Fungicide		
	Nissodium	Fungicide		


Table 1: Products launched over FY15-1HFY21

Source: Company; Antique





Table 3: Revenue and revenue growth



Source: Company; Antique





Table 4: EBITDA & EBITDA Margins (%)





Source: Company; Antique





Table 6: Steady cash flow generation

Source: Company; Antique

Table 7: Return ratios(%)



Source: Company; Antique

Source: Company; Antique

Financials

Profit and loss account (INRm)

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
Net Revenue	10,058	11,201	13,665	15,031	16,534
Op. Expenses	8,598	9,466	11,205	12,281	13,475
EBITDA	1,460	1,735	2,460	2,751	3,060
Depreciation	123	164	159	168	177
EBIT	1,336	1,571	2,300	2,583	2,883
Other income	212	251	326	489	636
Interest Exp.	9	16	15	15	15
Reported PBT	1,540	1,806	2,612	3,057	3,504
Tax	414	392	658	770	883
Reported PAT	1,126	1,415	1,953	2,286	2,621
Net Profit	1,126	1,415	1,953	2,286	2,621
Adjusted PAT	1,126	1,415	1,953	2,286	2,621
Adjusted EPS (INR)	23.7	29.7	41.1	48.1	55.1

Balance sheet (INRm)

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
Share Capital	95	95	95	95	95
Reserves & Surplus	6,327	6,981	8,533	10,361	12,524
Networth	6,422	7,076	8,628	10,456	12,619
Debt	222	80	-	-	-
Net deferred Tax liabilities	122	53	53	53	53
Capital Employed	6,766	7,209	8,682	10,510	12,672
Gross Fixed Assets	1,542	1,692	1,792	1,892	1,992
Accumulated Depreciation	373	518	677	845	1,023
Capital work in progress	10	37	10	10	11
Net Fixed Assets	1,179	1,211	1,125	1,057	981
Investments	1,203	1,589	1,589	1,589	1,589
Non Current Investments	898	991	991	991	991
Current Investments	305	597	597	597	597
Current Assets, Loans & Adv.	5,972	6,522	8,459	10,669	13,270
Inventory	2,068	2,499	2,984	3,272	3,599
Debtors	2,187	2,424	2,957	3,253	3,578
Cash & Bank balance	14	263	1,181	2,808	4,756
Loans & advances and others	1,703	1,337	1,337	1,337	1,337
Current Liabilities & Prov.	1,587	2,113	2,491	2,805	3,167
Liabilities	775	1,132	1,352	1,482	1,631
Provisions	812	981	1,139	1,323	1,537
Net Current Assets	4,385	4,409	5,968	7,864	10,103
Application of Funds	6,766	7,209	8,682	10,510	12,672

Per share data

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
No. of shares (m)	48	48	48	48	48
Diluted no. of shares (m)	48	48	48	48	48
BVPS (INR)	135.0	148.7	181.3	219.8	265.2
CEPS (INR)	26.3	33.2	44.4	51.6	58.8
DPS (INR)	0.6	12.0	7.0	8.0	8.0

Source: Company, Antique

Cash flow statement (INRm)

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
PBT	1,540	1,805	2,612	3,057	3,504
Depreciation & amortisation	123	164	159	168	177
Interest expense	9	16	15	15	15
(Inc)/Dec in working capital	(969)	158	(641)	(269)	(290)
Tax paid	(542)	(363)	(658)	(770)	(883)
Less: Interest/Div. Income Received	(87)	(142)	(326)	(489)	(636)
Other operating Cash Flow	(30)	(16)	-	-	-
CF from operating activities	43	1,621	1,161	1,711	1,887
Capital expenditure	(47)	(94)	(73)	(100)	(101)
Inc/(Dec) in investments	681	(361)	-	-	-
Add: Interest/Div. Income Received	88	12	326	489	636
CF from investing activities	721	(443)	253	389	535
Inc/(Dec) in debt	175	(142)	(80)	-	-
Dividend Paid	(207)	(772)	(401)	(458)	(458)
Others	(834)	(16)	(15)	(15)	(15)
CF from financing activities	(866)	(930)	(496)	(473)	(473)
Net cash flow	(101)	247	918	1,627	1,948
Opening balance	119	17	265	1,182	2,810
Closing balance	17	265	1,182	2,810	4,758

Growth indicators (%)

FY19	FY20	FY21e	FY22e	FY23e
4.5	11.4	22.0	10.0	10.0
-12.1	18.8	41.8	11.8	11.2
-10.8	25.7	38.1	17.0	14.6
-8.0	25.7	38.1	17.0	14.6
	4.5 -12.1 -10.8	4.5 11.4 -12.1 18.8 -10.8 25.7	4.5 11.4 22.0 -12.1 18.8 41.8 -10.8 25.7 38.1	4.5 11.4 22.0 10.0 -12.1 18.8 41.8 11.8 -10.8 25.7 38.1 17.0

Valuation (x)

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
P/E	31.1	24.8	18.0	15.3	13.4
P/BV	5.5	5.0	4.1	3.4	2.8
ev/ebitda	24.7	20.4	14.0	11.9	10.1
EV/Sales	3.6	3.2	2.5	2.2	1.9
Dividend Yield (%)	0.1	1.6	0.9	1.1	1.1

Financial ratios

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
RoE (%)	17.7	21.0	24.9	24.0	22.7
RoCE (%)	23.3	26.1	33.1	32.0	30.4
Asset/T.O (x)	2.0	2.0	2.1	1.9	1.7
Net Debt/Equity (x)	(0.0)	(0.1)	(0.2)	(0.3)	(0.4)
EBIT/Interest (x)	173.4	117.0	175.1	204.8	234.6

Margins (%)

Year ended 31 Mar	FY19	FY20	FY21e	FY22e	FY23e
EBITDA Margin(%)	14.5	15.5	18.0	18.3	18.5
EBIT Margin(%)	13.3	14.0	16.8	17.2	17.4
PAT Margin(%)	11.0	12.4	14.0	14.7	15.3

Source: Company Antique

Important Disclaimer:

This report has been prepared by Antique Stock Broking Limited (hereinafter referred to as ASBL) to provide information about the company(ies) and/sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies).

ASBL is a Stock Broker having SEBI Registration No. INZ000001131 and Depository Participant having SEBI Registration No. IN-DP-CDSL-726-2014 registered with and regulated by Securities & Exchange Board of India.

ASBL and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group.

This report is for personal information of the selected recipient/s and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and ASBL is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.

We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that ASBL and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of ASBL which may include earnings from investment banking and other business.

ASBL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, ASBL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary among other things, may give rise to real or potential conflicts of interest. ASBL and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial information and opinions; however the same shall have no bearing whatsoever on the specific recommendations much by the analyst(s) are completely independent of the views of the affiliates of ASBL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition ASBL has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt ASBL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold ASBL or any of its affiliates or employees repansibile for any such misuse and further agrees to hold ASBL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent ASBL's interpretation of the data, information and/ or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information. Also there may be regulatory, compliance, or other reasons that may prevent ASBL and/or its affiliates from doing so. ASBL or any of its affiliates or employees do not be in any way responsible and liable for any loss or damage that may preson from any inadvertent error in the information contained in this report. ASBL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

ASBL and it's associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

ASBL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of ASBL or its associates during twelve months preceding the date of distribution of the research report

ASBL and/or its affiliates and/or employees and /or relatives may have interests/positions, financial or otherwise of over 1 % at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, ASBL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of ASBL research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

Disclosure of Interest Statement Companies where there is interest

- Analyst ownership of the stock No
- Served as an officer, director or employee No

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASBL & its group companies to registration or licensing requirements within such jurisdictions.

For U.S. persons only: This research report is a product of Antique Stock Broking Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investor. Antique Stock Broking Limited has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

SEBI Registration Number: INH000001089 as per SEBI (Research Analysts) Regulations, 2014.

CIN: U67120MH1994PLC079444



Antique Stock Broking Limited

20th Floor, A Wing, Naman Midtown Senapati Bapat Marg, Elphinstone (West) Mumbai 400013 Tel. : +91 22 4031 3444 • Fax : +91 22 4031 3445 www.antiguelimited.com

